scholarly article | Q13442814 |
P50 | author | Mads Melbye | Q28759321 |
Soffia Gudbjörnsdottir | Q60608171 | ||
Peter Ueda | Q63819496 | ||
Ann-Marie Svensson | Q98840964 | ||
Kristian Hveem | Q32984975 | ||
Björn Pasternak | Q50561779 | ||
P2093 | author name string | Björn Eliasson | |
Henrik Svanström | |||
Christian Jonasson | |||
Stefan Franzén | |||
P2860 | cites work | The Danish National Patient Registry: a review of content, data quality, and research potential | Q26775834 |
Acute kidney injury from SGLT2 inhibitors: potential mechanisms. | Q53796258 | ||
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS | Q63071443 | ||
Canagliflozin-Associated Acute Pancreatitis | Q85248009 | ||
Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co-morbidity | Q86654822 | ||
Diabetes: SGLT2 inhibitors and diabetic ketoacidosis - a growing concern | Q88326701 | ||
SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System | Q88579083 | ||
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects | Q95561229 | ||
Performance and limitations of administrative data in the identification of AKI. | Q30741347 | ||
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials. | Q33890770 | ||
External review and validation of the Swedish national inpatient register | Q33928068 | ||
Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials | Q34664185 | ||
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
Canagliflozin-induced pancreatitis: a rare side effect of a new drug. | Q35811434 | ||
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. | Q35968414 | ||
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin | Q36431654 | ||
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus | Q36431670 | ||
The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application | Q36653410 | ||
Multiple imputation: review of theory, implementation and software | Q36719605 | ||
Possible adverse effects of SGLT2 inhibitors on bone | Q36988902 | ||
Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study | Q37454809 | ||
Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria | Q38188185 | ||
Ketoacidosis and SGLT2 inhibitor treatment: Analysis of FAERS data. | Q38665387 | ||
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes | Q38962076 | ||
Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations | Q45183983 | ||
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes | Q46113283 | ||
Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database | Q47366627 | ||
Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis | Q47652080 | ||
One-to-many propensity score matching in cohort studies. | Q47789199 | ||
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials | Q47918474 | ||
Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial | Q48313349 | ||
Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study | Q48360915 | ||
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? | Q48374438 | ||
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. | Q49988613 | ||
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real W | Q50042476 | ||
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. | Q50955035 | ||
Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. | Q51032023 | ||
Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. | Q51737719 | ||
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. | Q53084508 | ||
P407 | language of work or name | English | Q1860 |
P304 | page(s) | k4365 | |
P577 | publication date | 2018-11-14 | |
P1433 | published in | The BMJ | Q546003 |
P1476 | title | Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study | |
P478 | volume | 363 |
Q92535991 | Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program |
Q64355352 | Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation |
Q92028398 | Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey |
Q92544099 | Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study |
Q92131836 | Class effect for SGLT-2 inhibitors: a tale of 9 drugs |
Q90259243 | Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study |
Q64245217 | Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program |
Q64904716 | Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. |
Q95282509 | Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report |
Q91937581 | Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes |
Q90465947 | Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes |
Q92835456 | Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes |
Q92462642 | Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease |
Q90676214 | SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects |
Q92703271 | SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects |
Q92853232 | SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects |
Q98778627 | Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus |
Q89963471 | Therapeutic Inertia in Pediatric Diabetes: Challenges to and Strategies for Overcoming Acceptance of the Status Quo |
Q92992644 | Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study |
Q94554818 | Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study |
Search more.